ResMed Crecimiento futuro
Future controles de criterios 2/6
Se prevé un crecimiento anual de los beneficios y los ingresos de ResMed de 13.5% y 7.1% por año respectivamente. Se prevé que el BPA crezca en un 12.8% al año. Se espera que la rentabilidad financiera sea de 22.2% en 3 años.
Información clave
11.5%
Tasa de crecimiento de los beneficios
11.4%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Medical Equipment | 17.4% |
| Tasa de crecimiento de los ingresos | 6.5% |
| Rentabilidad financiera futura | 21.9% |
| Cobertura de analistas | Good |
| Última actualización | 13 Aug 2024 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
ResMed (NYSE:RMD) Is Increasing Its Dividend To $0.53
Aug 05
Does ResMed (NYSE:RMD) Have A Healthy Balance Sheet?
Jul 29Returns On Capital Are A Standout For ResMed (NYSE:RMD)
Jul 15ResMed: Asymmetrical Value Opportunity With High Prospect Of Re-Rating
Jul 03An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 33% Undervalued
Jul 02ResMed (NYSE:RMD) Seems To Use Debt Quite Sensibly
Apr 30Earnings Beat: ResMed Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Apr 30ResMed Inc.'s (NYSE:RMD) Popularity With Investors Is Clear
Apr 18With EPS Growth And More, ResMed (NYSE:RMD) Makes An Interesting Case
Mar 22Capital Investments At ResMed (NYSE:RMD) Point To A Promising Future
Mar 10An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 30% Undervalued
Feb 12Why ResMed Is One Of My Top Picks In 2024
Jan 22A First Look At ResMed
Jan 09ResMed Inc.'s (NYSE:RMD) Share Price Could Signal Some Risk
Dec 20Why You Should Care About ResMed's (NYSE:RMD) Strong Returns On Capital
Dec 06Shareholders May Find It Hard To Justify Increasing ResMed Inc.'s (NYSE:RMD) CEO Compensation For Now
Nov 10Are Investors Undervaluing ResMed Inc. (NYSE:RMD) By 41%?
Nov 01ResMed: Weight-Loss Drug Worries Provide Buying Opportunity
Oct 28ResMed: Stock Re-Rating To 20x Forward P/E Is A Buy Opportunity
Sep 12ResMed Has Become A Steal (Rating Upgrade)
Aug 10ResMed's (NYSE:RMD) Shareholders Will Receive A Bigger Dividend Than Last Year
Aug 07ResMed (NYSE:RMD) Has Some Way To Go To Become A Multi-Bagger
Jul 30Here's Why We Think ResMed (NYSE:RMD) Might Deserve Your Attention Today
Jul 16Compound Your Wealth With ResMed
Jul 04A Look At The Fair Value Of ResMed Inc. (NYSE:RMD)
Jul 02We Think ResMed (NYSE:RMD) Can Stay On Top Of Its Debt
May 26ResMed (NYSE:RMD) Could Be Struggling To Allocate Capital
Apr 24Here's Why ResMed (NYSE:RMD) Has Caught The Eye Of Investors
Apr 09A Look At The Intrinsic Value Of ResMed Inc. (NYSE:RMD)
Mar 26ResMed goes ex dividend tomorrow
Feb 07ResMed (NYSE:RMD) Seems To Use Debt Quite Sensibly
Feb 06Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 6/30/2027 | 5,736 | 1,561 | 1,545 | 1,677 | 15 |
| 6/30/2026 | 5,397 | 1,433 | 1,463 | 1,575 | 20 |
| 6/30/2025 | 5,054 | 1,297 | 1,206 | 1,359 | 21 |
| 6/30/2024 | 4,685 | 1,021 | 1,286 | 1,401 | N/A |
| 3/31/2024 | 4,584 | 958 | 1,071 | 1,199 | N/A |
| 12/31/2023 | 4,504 | 890 | 944 | 1,079 | N/A |
| 9/30/2023 | 4,375 | 907 | 792 | 935 | N/A |
| 6/30/2023 | 4,223 | 898 | 559 | 693 | N/A |
| 3/31/2023 | 4,016 | 863 | 408 | 535 | N/A |
| 12/31/2022 | 3,763 | 809 | 222 | 370 | N/A |
| 9/30/2022 | 3,624 | 786 | 305 | 461 | N/A |
| 6/30/2022 | 3,578 | 779 | 195 | 351 | N/A |
| 3/31/2022 | 3,539 | 779 | 344 | 498 | N/A |
| 12/31/2021 | 3,444 | 522 | 446 | 577 | N/A |
| 9/30/2021 | 3,349 | 500 | 397 | 527 | N/A |
| 6/30/2021 | 3,197 | 475 | 620 | 737 | N/A |
| 3/31/2021 | 3,091 | 457 | 733 | 840 | N/A |
| 12/31/2020 | 3,092 | 699 | 774 | 884 | N/A |
| 9/30/2020 | 3,028 | 680 | 684 | 784 | N/A |
| 6/30/2020 | 2,957 | 622 | 696 | 802 | N/A |
| 3/31/2020 | 2,892 | 513 | 505 | 614 | N/A |
| 12/31/2019 | 2,784 | 455 | 420 | 514 | N/A |
| 9/30/2019 | 2,699 | 419 | 487 | 573 | N/A |
| 6/30/2019 | 2,607 | 405 | 382 | 459 | N/A |
| 3/31/2019 | 2,525 | 446 | 374 | 447 | N/A |
| 12/31/2018 | 2,455 | 450 | 385 | 456 | N/A |
| 9/30/2018 | 2,405 | 335 | 390 | 459 | N/A |
| 6/30/2018 | 2,340 | 316 | 434 | 505 | N/A |
| 3/31/2018 | 2,273 | 307 | N/A | 516 | N/A |
| 12/31/2017 | 2,196 | 285 | N/A | 434 | N/A |
| 9/30/2017 | 2,125 | 352 | N/A | 422 | N/A |
| 6/30/2017 | 2,067 | 342 | N/A | 414 | N/A |
| 3/31/2017 | 2,029 | 324 | N/A | 417 | N/A |
| 12/31/2016 | 1,968 | 327 | N/A | 474 | N/A |
| 9/30/2016 | 1,893 | 346 | N/A | 510 | N/A |
| 6/30/2016 | 1,839 | 352 | N/A | 548 | N/A |
| 3/31/2016 | 1,773 | 357 | N/A | 505 | N/A |
| 12/31/2015 | 1,742 | 357 | N/A | 471 | N/A |
| 9/30/2015 | 1,710 | 353 | N/A | 421 | N/A |
| 6/30/2015 | 1,679 | 353 | N/A | 383 | N/A |
| 3/31/2015 | 1,641 | 353 | N/A | 399 | N/A |
| 12/31/2014 | 1,616 | 352 | N/A | 409 | N/A |
| 9/30/2014 | 1,578 | 348 | N/A | 387 | N/A |
| 6/30/2014 | 1,555 | 345 | N/A | 391 | N/A |
| 3/31/2014 | 1,554 | 331 | N/A | 400 | N/A |
| 12/31/2013 | 1,540 | 325 | N/A | 406 | N/A |
| 9/30/2013 | 1,532 | 317 | N/A | 415 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (13.5% al año) de RMD es superior a la tasa de ahorro (2.4%).
Beneficios vs. Mercado: Se prevé que los beneficios (13.5% al año) de RMD crezcan menos que el mercado US (14.8% al año).
Beneficios de alto crecimiento: Se prevé que los beneficios de RMD crezcan, pero no significativamente.
Ingresos vs. Mercado: Se prevé que los ingresos (7.1% al año) de RMD crezcan más despacio que el mercado de US (8.7% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos 7.1% al año) de RMD crezcan más despacio que 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Se prevé que la rentabilidad financiera de RMD sea alta dentro de 3 años (22.2%)